Healius Limited: Improving Operations Amid Reported Loss
Healius Limited (ASX: HLS) is one of Australia’s leading healthcare companies, providing specialty pathology services nationwide through an extensive network of laboratories and collection centres. In 1H FY26, the company delivered revenue of AU$688.1 million, up 3.8% year-on-year, supported by improved revenue mix and growth in higher-margin segments such as Genomics, Clinical Trials, and Veterinary Pathology.
Underlying EBITDA increased 13.1% to AU$122.2 million, while underlying EBIT improved to AU$7.9 million from a prior-period loss, reflecting early benefits from cost optimisation and digital transformation initiatives. Pathology revenue rose 3.5% to AU$666.3 million, and disciplined cost management limited total cost growth to 1.9%. Agilex Biolabs recorded strong momentum, with revenue up 16.0% and EBIT more than doubling.
Despite operational improvement, Healius reported a statutory net loss after tax of AU$30.4 million, primarily impacted by non-underlying items, restructuring costs and digital transformation expenses. The company ended the period with net cash of AU$11.6 million and continues to target high single-digit EBIT margins by FY27 through productivity gains and revenue mix enhancement.
Customer Notice:
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.
Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com.au
x
Daily Dose of Buy, Sell & Hold recommendations before the market opens.
Start Your 7 Days Free Trial Now!
We use cookies to help us improve, promote, and protect our services.
By continuing to use this site, we assume you consent to this.
Read our
Privacy Policy
and
Terms & Conditions
Healius Limited: Improving Operations Amid Reported Loss
Healius Limited (ASX: HLS) is one of Australia’s leading healthcare companies, providing specialty pathology services nationwide through an extensive network of laboratories and collection centres. In 1H FY26, the company delivered revenue of AU$688.1 million, up 3.8% year-on-year, supported by improved revenue mix and growth in higher-margin segments such as Genomics, Clinical Trials, and Veterinary Pathology.
Underlying EBITDA increased 13.1% to AU$122.2 million, while underlying EBIT improved to AU$7.9 million from a prior-period loss, reflecting early benefits from cost optimisation and digital transformation initiatives. Pathology revenue rose 3.5% to AU$666.3 million, and disciplined cost management limited total cost growth to 1.9%. Agilex Biolabs recorded strong momentum, with revenue up 16.0% and EBIT more than doubling.
Despite operational improvement, Healius reported a statutory net loss after tax of AU$30.4 million, primarily impacted by non-underlying items, restructuring costs and digital transformation expenses. The company ended the period with net cash of AU$11.6 million and continues to target high single-digit EBIT margins by FY27 through productivity gains and revenue mix enhancement.
Customer Notice:
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.
Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com.au